2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

9:00AM-11:00AM: Abstract Number: 1744

Free DKK-1 Serum Levels Are Unchanged in Spondyloarthritis Patients Treated By Etanercept

Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1155

Free Fatty Acids Promote Inflammation in Bone of Rheumatic Patients Via Osteoblast

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1805

Functional and Mechanistic Characterization of Anifrolumab, a Fully Human, Anti-IFNAR1 Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1867

Functional Androgen Receptor Variants Associated with Greater Damage in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1360

Functional Consequences of NOD2 Gene Variants in Patients with NOD2-Associated Autoinflammatory Disease

Innate Immunity and Rheumatic Disease Poster II

9:00AM-11:00AM: Abstract Number: 1173

G Protein Coupled Receptor Kinase 3 Regulation of Inflammatory Arthritis

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1256

Gas Chromatography/Time-of-Flight-Mass Spectrometry-Based Metabolomic Profiling in Cultured Fibroblast-like Synoviocytes from Rheumatoid Arthritis

Genetics, Genomics and Proteomics Poster II

9:00AM-11:00AM: Abstract Number: 1743

Gender Differences in Ankylosing Spondylitis: Men Derive Greater Benefit from Tumor Necrosis Factor Alpha Inhibitors

Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1246

Gene Expression Analysis of Adult Onset Still’s Disease and Systemic Juvenile Idiopathic Arthritis Suggest a Single Disease Continuum

Genetics, Genomics and Proteomics Poster II

9:00AM-11:00AM: Abstract Number: 1611

Gene Expression Profiling Reflects Increased Expression of Coronary Artery Disease Associated Genes in a Case-Control Matched Study of Patient with Rheumatoid Arthritis

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1949

Generation and Immunophenotyping of Citrullin-Specific T Cell Lines from Peripheral Blood and Synovial Fluid of ACPA+ RA Patients

T cell Biology and Targets in Autoimmune Disease Poster I

9:00AM-11:00AM: Abstract Number: 1265

Genetic and Epigenetic Mapping of Very Early RA Synovial Fibroblasts

Genetics, Genomics and Proteomics Poster II

9:00AM-11:00AM: Abstract Number: 1621

Genetic Contributions to Radiographic Damage in African Americans with Rheumatoid Arthritis on a Panel of Autoimmune Disease Markers

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1919

Genetic Deletion of Toll-like Receptor 4 (Tlr4) Abrogates TGF-β1-Induced Endothelial-to-Mesenchymal Transition (EndoMT) in Murine Pulmonary Endothelial Cells

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster I

9:00AM-11:00AM: Abstract Number: 1619

Genetic Influences of Susceptibility to Rheumatoid Arthritis in African Americans

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].